Scarica l'app Stockscreener
6.26
2.03%
-0.13
Dopo l'orario di chiusura:
6.30
0.04
+0.64%
Precedente Chiudi:
$6.39
Aprire:
$6.26
Volume 24 ore:
60,432
Relative Volume:
0.32
Capitalizzazione di mercato:
$165.95M
Reddito:
$2.80M
Utile/perdita netta:
$-130.30M
Rapporto P/E:
-1.2463
EPS:
-5.0228
Flusso di cassa netto:
$-79.40M
1 W Prestazione:
+2.96%
1M Prestazione:
-17.63%
6M Prestazione:
-39.46%
1 anno Prestazione:
-51.66%
Intervallo 1D:
$6.16
$6.36
Intervallo di 1 settimana:
$5.60
$6.50
Portata 52W:
$5.60
$15.57
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
6.26 | 165.95M | 2.80M | -130.30M | -79.40M | -5.0228 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
If You Invested $1,000 in Cartesian (RNAC) - Stock Titan
Near-20% holder updates Cartesian Therapeutics (RNAC) stake and board role - Stock Titan
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian gives two new hires stock options at $6.39 a share - Stock Titan
RNAC Technical Analysis & Stock Price Forecast - Intellectia AI
Published on: 2026-04-01 20:53:55 - baoquankhu1.vn
Big Money Moves: Should I invest in Cartesian Therapeutics Inc before earningsEarnings Summary Report & Smart Allocation Stock Tips - baoquankhu1.vn
Inflation Data: Does Cartesian Therapeutics Inc have declining or rising EPSMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Merger Talk: Will Cartesian Therapeutics Inc outperform the market in YEAR2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 - Investing.com UK
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation - TipRanks
Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 By Investing.com - Investing.com South Africa
Murat Kalayoglu to Resign from Cartesian Board, Leaving Science & Technology Committee - TradingView
Board member Murat Kalayoglu to leave Cartesian Therapeutics (RNAC) board March 31, 2026 - Stock Titan
Treasury Yields: Why is Cartesian Therapeutics Inc stock going down2026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Energy Moves: Is Cartesian Therapeutics Inc benefiting from interest rate changesMarket Activity Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Patterns: Will Cartesian Therapeutics Inc outperform during market ralliesEarnings Summary Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Trading Action: Will Cartesian Therapeutics Inc outperform during market ralliesPortfolio Gains Report & High Accuracy Buy Signal Tips - baoquankhu1.vn
Swing Trade: Is Cartesian Therapeutics Inc benefiting from interest rate changesQuarterly Profit Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Published on: 2026-03-26 03:38:41 - baoquankhu1.vn
Insiders' US$1.73m Investments In Red Following Cartesian Therapeutics' US$29m Dip In Market Value - simplywall.st
Published on: 2026-03-22 15:23:24 - baoquankhu1.vn
Investment Review: Is Cartesian Therapeutics Inc showing insider buyingWeekly Gains Summary & Risk Controlled Daily Plans - baoquankhu1.vn
Squarepoint Ops LLC Acquires Significant Stake in Cartesian Therapeutics Inc - GuruFocus
Bear Alert: Why is Cartesian Therapeutics Inc stock going downPrice Action & AI Driven Stock Reports - baoquankhu1.vn
Cartesian Therapeutics (RNAC) director Michael Singer gifts 6,555 shares - Stock Titan
Squarepoint entities disclose multi-affiliate stakes in Cartesian Therapeutics (RNAC) — 8.3% each - Stock Titan
Published on: 2026-03-13 09:11:18 - baoquankhu1.vn
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch - TipRanks
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Growth Recap: Does Cartesian Therapeutics Inc have declining or rising EPS2026 Retail Activity & Stock Portfolio Risk Management - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Myasthenia Gravis Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart
Wedbush Reiterates 'Outperform' Rating on RNAC | RNAC Stock News - GuruFocus
Cantor Fitzgerald upgrades Cartesian Therapeutics (RNAC) - MSN
Cartesian Therapeutics' (RNAC) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded to “Overweight” at Cantor Fitzgerald - Defense World
BTIG reiterates Buy on Cartesian Therapeutics stock, $44 target By Investing.com - Investing.com Canada
Cartesian Therapeutics Reports 2025 Financial Results, Advances Descartes-08 Cell Therapy in Autoimmune Diseases and Myasthenia Gravis Phase 3 Trial - Minichart
Mizuho reiterates Cartesian Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Cartesian Therapeutics (RNAC) Upgraded to Overweight by Cantor F - GuruFocus
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics, Inc. 2025 Annual Report – Pipeline, Clinical Trials, Regulatory Approvals, and Competitive Landscape - Minichart
Cantor Fitzgerald Upgrades Cartesian Therapeutics (NASDAQ:RNAC) to Overweight - MarketBeat
Cartesian Therapeutics Inc expected to post a loss of 85 cents a shareEarnings Preview - TradingView
Cartesian Therapeutics posts full year 2025 financial results and issues business update - Traders Union
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):